
Diamond Therapeutics initiates dosing in first-ever Phase 2a clinical trial evaluating low-dose psilocybin for anxiety
Double-blind, placebo-controlled study explores daily non-psychedelic doses of psilocybin for individuals with Generalized Anxiety Disorder TORONTO, ONTARIO, CANADA, July 30, 2025 /EINPresswire.com/ -- Diamond Therapeutics Inc. ("Diamond…